Mandal, Manisha published the artcileBioinformatic approaches for identification of potential repurposable drugs in COVID-19, Quality Control of 55981-09-4, the main research area is drug reporposing antiviral MYC ABCG rapamycin gene SARSCoV2 coronavirus.
Repurposing existing drugs approved for other conditions is crucial to identifying specific therapeutics against SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) causing COVID-19 (coronavirus disease 2019) pandemic. Towards this attempt, it is important to understand how this virus hijacks the host system during the course of infection and determine potential virus- and host-targeted inhibitors. This study elucidates the underlying virus-host interaction based on differentially expressed gene profiling, functional enrichment and pathway anal., protein-protein and protein-drug interactions utilizing the information on transcriptional response to SARS-CoV-2 infection from GSE147507 dataset containing COVID-19 case relative to healthy control and infected cell culture compared to uninfected one. Low IFN signaling, chemokines level elevation, and proinflammatory cytokines release were observed markedly. We identified MYC-rapamycin and ABCG2-rapamycin interactions, and unique gene signatures in case (regulation of protein modification and MAPK signaling) as well as in cell (metabolic dysregulation and interferon signaling) different from known COVID-19 genes. Among a plethora of repurposable drugs those appearing here with unique gene signatures might be helpful in COVID-19.
Journal of Drug Delivery and Therapeutics published new progress about Animal gene, c-myc Role: BSU (Biological Study, Unclassified), BIOL (Biological Study). 55981-09-4 belongs to class esters-buliding-blocks, name is 2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate, and the molecular formula is C12H9N3O5S, Quality Control of 55981-09-4.
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics